14 results about "Dopamine agonist" patented technology

Sublingual compositions for the treatment of erectile dysfunction (ED) comprise unique combinations of phosphodiesterase-type 5 (PDE5) inhibitors and D1 / D2 dopamine receptor agonists. In preferred embodiments, a combination of four drug actives exhibits a full range of effectiveness for ED in which there is a short and long acting PDE5 inhibitor in combination with both a dopamine agonist and a CNS hormone to provide both a physiological response and a psychological / CNS action. A treatment for ED comprises administration of sublingual compositions in the physical form of sublingual tablets.

Compositions and methods for treating neurological conditions are provided. The present invention provides a pharmaceutical composition comprising a dopamine reuptake inhibitor or dopamine agonist, an adrenergic receptor antagonist, and a pharmaceutically acceptable carrier, and a method for treating a neurological disorder by administering the composition.

The present invention relates to methods and devices for providing a treatment recommendation based on a prediction of at least one Impulse Control Disorder occurrence for a patient undergoing a treatment with Dopamine Agonists.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

1. The name of the design product: long handle hair stick (Dopamine). 2. The use of the design product: for hair stick. 3. The design points of the design product: in shape. 4. The picture or photo that best shows the design points: perspective view.

This invention relates to combination therapy of a subject suffering from acromegaly. The method of treatment comprises administration to the subject of a therapeutically effective amount of oral somatostatin receptor ligand (SRL) e.g. octreotide in combination with a therapeutically effective amount of a dopamine agonist and / or a growth hormone receptor antagonist and / or a selective estrogen receptor modulator (SERM) and / or a 2nd somatostatin receptor ligand (SRL).

The invention provides a novel pharmaceutical composition comprising a phosphodiesterase type 5 (PDE5) inhibitor other than sildenafil and a dopamine agonist and method of use thereof for treating erectile dysfunction and / or male hypogonadism.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

The invention discloses a quinolinone double-ligand derivative and an application of the quinolinone double-ligand derivative as a dopamine D2R agonist. According to the invention, n-propyl indene-2-amine is used as a normal ligand fragment, quinolinone or indolone is used as an allosteric ligand fragment, and an intermediate LINKER part is connected by a methylene carbon chain and a cyclohexyl carbon chain with different lengths to obtain the dopamine D2R agonist as shown in a formula (1) and a formula (2). According to the invention, the functional activity of all compounds on D2R on a G protein dependent signaling pathway is tested through a GloSensor cAMP accumulation experiment. Pharmacological results show that all the synthesized target compounds have good agonistic activity on D2R, that is, the target compounds of the invention are D2R agonists. # imgabs0 #

The invention relates to the technical field of yang tonifying, and discloses a hippocampus and pilose antler essence health-care paste which mainly comprises 30 g of actinolite, 30 g of morinda officinalis, 5 g of pilose antler, 5 g of hippocampus, 30 g of radix cyathulae, 50 g of herba epimedii, 15 g of cynomorium songaricum, 15 g of eucommia ulmoides, 15 g of semen cuscutae, 30 g of schisandra chinensis, 30 g of ligusticum wallichii, 30 g of cinnamon, 15 g of ginger, 50 g of cistanche, 30 g of salvia miltiorrhiza, 30 g of clove, 30 g of fructus cnidii, 50 g of radix polygoni multiflori preparata, 15 g of rhizoma polygonati and 30 g of rhizoma acori graminei Compared with other products in the market, the health-care wine does not contain nafil, ramine, caine and oxetine drugs, also contains the components such as a phosphodiesterase (PDE5) inhibitor, an adrenergic receptor blocker, a dopamine agonist, an anesthetic and capsaicin, does not cause damage to the body after being drunk, does not affect the effect, and is safe and reliable. Adverse reactions such as dizziness, headache, abdominal distension, nausea, persistent excitation, sexual overdraft and the like are not generated.

The present invention addresses the problem of providing a medicine that, despite of being a non-ergot dopamine agonist (DA), reduces the risk of the drowsiness side effect, and exhibits an excellent therapeutic effect on neurodegenerative disorders such as Parkinson's disease (PD). The present invention relates to a pharmaceutical composition for treating neurodegenerative diseases such as Parkinson's disease, the pharmaceutical composition comprising 1-{[(4aR,6R,8aR)-2-amino-3-cyano-8-methyl-4,4a,5,6,7,8,8a,9-octahydrothieno[3,2-g]quinolin-6-yl]carbonyl}-3-[2-(dimethylamino)ethyl]-1-propylurea or a pharmacologically acceptable salt thereof. The pharmaceutical composition is characterized by being orally administered at a daily dose of 0.25 mg to 2 mg in terms of free form.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.

The present invention relates to the use of nicotinic acetylcholine receptor alpha 7 activators, in particular to the use of nicotinic acetylcholine receptor alpha 7 agonists for the treatment, prevention or delay of progression of dyskinesia associated with dopamine agonist therapy in Parkinson's disease.

The application describes a method of reducing emesis caused by a dopamine agonist in a patient with depression who is treated with a dopamine agonist, comprising administering ondansetron in combination with the dopamine agonist.